Evidence map›Paper›PMID 33837906›Full record

Trial reportInternal and emergency medicine2021

A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm.

Mandana Pouladzadeh, Mehdi Safdarian, Peyman Eshghi, Hassan Abolghasemi, Alireza Ghorbani Bavani, Behnam Sheibani, Parastoo Moradi Choghakabodi, Abdolaziz Feghhi, Mehri Ghafourian Boroujerdnia, Arash Forouzan and 7 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Internal and emergency medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 18 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 18 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 18 syntheses or guidelines pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Trial
  20. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Mandana PouladzadehEmergency Medicine Department, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Mehdi SafdarianNanotechnology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. msafdaryan@gmail.com.ORCID http://orcid.org/0000-0001-9735-2632
Peyman EshghiPediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hassan AbolghasemiApplied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Alireza Ghorbani BavaniRadiology Department, Abadan University of Medical Sciences, Abadan, Iran.
Behnam SheibaniInfectious Diseases Department, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Parastoo Moradi ChoghakabodiThalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. parastoomoradi40@yahoo.com.ORCID http://orcid.org/0000-0002-6362-7842
Abdolaziz FeghhiBlood Transfusion Organization, Ahvaz, Khuzestan, Iran.
Mehri Ghafourian BoroujerdniaDepartment of Immunology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Arash ForouzanDepartment of Emergency Medicine, Imam Khomeini General Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Mohammad Ali Jalali FarThalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Gholam Abbas KaydaniDepartment of Laboratory Sciences, Allied Health Sciences School, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Elham RajaeiDepartment of Internal Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Mansour AminDepartment of Microbiology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Mehdi TorabizadehGolestan Hospital Clinical Research Development Unit, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Farid YousefiInfectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz, Iran.
Reza HadaddezfuliAhvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Ahvaz Jundishapur University of Medical Sciences · IRBaqiyatallah University of Medical Sciences · IRHamedan University of Medical Sciences · IRHigh Institute for Education and Research in Transfusion Medicine · IR

Funding

Ahvaz Jundishapur University of Medical Sciences IR.AJUMS.REC.1399.003
6 · The paper itself

Abstract

Evaluating the effect of convalescent plasma (CP) on some cytokine storm indices in severe COVID-19 patients. Totally, 62 patients were randomly assigned into two groups for this clinical trial. Patients in the intervention group received one unit (500 mL) plasma on the admission day plus standard drugs while the controls merely received standard treatments. Eventually, primary and secondary outcomes were evaluated. In the CP group, compared with controls, the mean levels of lymphocytes and IL-10 significantly increased while the levels of IL-6, TNF-α, and IFN-γ decreased (p < 0.05). The length of in-hospital stay, and mortality rate did not significantly reduce in the CP group compared with controls (p > 0.05) while WHO severity scores remarkably improved (p = 0.01), despite the higher frequency of underlying diseases among the CP group (66.7%) vs. controls (33.3%). Although CP has a remarkable immunomodulatory and antiviral potential to improve the cytokine storm and disease severity in COVID-19 patients, it did not considerably affect the mortality rate.

Indexed as

Blood Component TransfusionAdultB-LymphocytesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCOVID-19COVID-19 SerotherapyCritical IllnessCytokine Release SyndromeFemaleHumansImmunization, PassiveInterleukin-10Interleukin-6Length of StayMaleInterleukin-10Interleukin-6Convalescent plasmaCOVID-19Cytokine storm

Identifiers

PMID33837906
PMCPMC8035885
OpenAlexW3144135259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.